Participants
disease or disorder, renal impairment, traumatic brain injury, stroke, toxic, encephalitis, Encephalitis
RENAL IMPAIRMENT, BACTERIAL MENINGITIS, STROKE, METABOLIC ENCEPHALOPATHY, ENCEPHALITIS, ENCEPHALITIS, HYPERCOAGULABLE STATE, DEMYELINATING DISORDER, HYPERPROLINAEMIA, HYPERTENSIVE ENCEPHALOPATHY
Eligible participants were hospitalised children aged between 6 weeks and 16 years who met the case definition for encephalitis based on the consensus definition by the International Encephalitis Consortium,Exclusion criteria were a high clinical suspicion of bacterial meningitis; prior receipt of IVIG during the admission or known contraindication to IVIG; traumatic brain injury; history of metabolic encephalopathy; stroke, toxic or hypertensive encephalopathy; pre-existing demyelinating disorder; significant renal impairment; hypercoagulable state; hyperprolinaemia; participation in another research trial involving an immunomodulatory treatment; pregnancy; any significant disease or disorder which may put the participants at risk because of participation in the trial, influence the result of the trial, or the participant’s ability to participate in the trial; involvement in another research trial involving an investigational medicinal product (IMP) which has potential immunomodulatory or neuroprotective effects.